AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook

Key Takeaways AstraZeneca posted Q4 core EPS of $2.12 and revenues of $15.5B, missing consensus estimates on both lines.AZN saw strong oncology demand, with Tagrisso up 10% and Imfinzi surging 37%, helping offset pricing.AstraZeneca guided 2026 mid-to-high single-digit revenue growth and low double-digit core EPS growth.AstraZeneca (AZN) reported fourth-quarter 2025 core earnings of $2.12 per share, which missed the Zacks Consensus Estimate of $2.18 per share. Earnings rose 1% year over year on a reported b ...